“I’m excited and honored to join the Idera team at this pivotal juncture and to help prepare the company for the anticipated success of tilsotolimod in advanced refractory melanoma and beyond ...

EXTON, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today announced that it will not continue ILLUMINATE-301, the Company’s ...

Texas-based Idera, Inc. announced it has acquired Yellowfin International Pty Ltd, a heretofore independent Business Intelligence (BI) company headquartered in Melbourne, Australia. Terms of the ...

Mr. Kirby has been the Company’s Vice President of Finance since July 2018. Before joining Idera in 2015, Mr. Kirby served as Assistant Controller at Endo Pharmaceuticals. Prior to joining Endo ...

BioCryst Pharmaceuticals Inc. and Idera Pharmaceuticals Inc. announced early Monday plans to merge into a rare disease company. Shares of both companies were halted in premarket trade. Under the ...

(RTTNews) - BioCryst Pharmaceuticals Inc. (BCRX) and Idera Pharmaceuticals Inc. (IDRA) announced that they have signed a definitive merger agreement. The combined company will be renamed upon ...

PALO ALTO, Calif.--(BUSINESS WIRE)--HGGC, a leading middle market private equity firm, today announced the signing of a definitive agreement to recapitalize IDERA (or “the Company”), a leading ...

What: Shares of Idera Pharmaceuticals, a clinical-stage biotechnology company focused on discovering novel drugs to modify immune responses through toll-like receptors, jumped as much as 13% after ...